Wordt geladen...
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater anti-estrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen co...
Bewaard in:
| Gepubliceerd in: | Clin Pharmacol Ther |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5931215/ https://ncbi.nlm.nih.gov/pubmed/29385237 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1007 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|